SEC Tracker
Get the app

Kinnate Biopharma

Kinnate Biopharma says Mark Meltz resigned as officers

Form
8-K
Filed
Period
Importance
Major
Document
8-K
  • Completes an acquisition or sale of assets (2.01)
  • Reports an exchange listing deficiency notice (3.01)
  • Changes shareholder rights (3.03)
  • Reports a change in control (5.01)
  • Reports an executive or board change (5.02)
  • Amends its charter or bylaws (5.03)
  • Discloses other events (8.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Kinnate Biopharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float not reported.

  1. Acura Pharmaceuticals ACUR
  2. Ayala Pharmaceuticals ADXS
  3. Ampio Pharmaceuticals AMPE
  4. Alterity Therapeutics ATHE
  5. Adhera Therapeutics ATRX

Data on this page was fetched . The filing on SEC.gov is the record.